Seres Therapeutics, Inc.
MCRB
$4.54
$0.061.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 105.59% | -18.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 105.59% | -18.26% | |||
| Cost of Revenue | -30.72% | 7.49% | |||
| Gross Profit | 34.53% | -8.44% | |||
| SG&A Expenses | -12.50% | 7.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.81% | 7.32% | |||
| Operating Income | 26.02% | -7.90% | |||
| Income Before Tax | 123.01% | -29.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 123.01% | -29.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 123.01% | -29.85% | |||
| EBIT | 26.02% | -7.90% | |||
| EBITDA | 26.48% | -9.24% | |||
| EPS Basic | 122.71% | -25.07% | |||
| Normalized Basic EPS | 27.56% | -15.53% | |||
| EPS Diluted | 122.60% | -25.19% | |||
| Normalized Diluted EPS | 27.56% | -15.53% | |||
| Average Basic Shares Outstanding | 1.29% | 3.82% | |||
| Average Diluted Shares Outstanding | 1.29% | 3.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||